Xiangmin Cui - 18 Jan 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Role
Director, 10%+ Owner
Signature
/s/ Xiangmin Cui
Issuer symbol
ALPN
Transactions as of
18 Jan 2024
Transactions value $
$15,729,263
Form type
4
Filing time
22 Jan 2024, 17:48:23 UTC
Previous filing
04 Jan 2024
Next filing
11 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Exercise of in-the-money or at-the-money derivative security $15.7M +1.23M +23.09% $12.74 6.58M 18 Jan 2024 See Footnote F1
holding ALPN Common Stock 1.74M 18 Jan 2024 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALPN Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -1.23M -100% $0.00* 0 18 Jan 2024 Common Stock 1.23M $12.74 See Footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
F2 These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.